Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing oral combination medicines and psychedelic-based therapies for chronic conditions with limited treatment options. Incannex Healthcare Inc. is currently advancing programs in obstructive sleep apnea, generalized anxiety disorder, rheumatoid arthritis, and inflammatory disorders through its research and development of cannabinoid and psychedelic pharmaceutical products. Its pipeline includes fixed-dose and synthetic oral treatments designed to target underlying biological pathways and support clinical development across sleep medicine, mental health, and inflammation. Based in Sydney, Australia, Incannex Healthcare Inc. operates as a science-led developer of novel therapeutics aimed at addressing significant unmet medical needs in modern healthcare.
Website8 Century Circuit
Sydney, NSW, 2153
Australia
What share of all stock conversation is about IXHL?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0.01% 0 | 0.01% 0 | 0.01% +0 | 0.04% -0.07 |
Of the messages about IXHL that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 90% +8.37 | 74.8% -7.71 | 79.34% -2.83 | 81.36% -0.99 | ||
| Bearish | 10% -8.37 | 25.2% +7.71 | 20.66% +2.83 | 18.64% +0.99 |
Of the messages about IXHL that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 53.85% | 75.93% | 30.22% | ||
| Technical Analysis | — | 46.15% | 24.07% | 46.28% | ||
| Macro | — | 0% | 0% | 7.51% | ||
| Controversies | — | 0% | 0% | 0.73% | ||
| Analysts | — | 0% | 0% | 14.65% | ||
| Earnings | — | 0% | 0% | 0.61% |
Of the messages about IXHL, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 97.87% | 97.65% | 98.81% | 79.46% | ||
| Newcomers | 2.13% | 2.35% | 1.19% | 20.54% |
First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI...
Detailed price information for Incannex Healthcare Inc ADR (IXHL-Q) from The Globe and Mail including charting and trades.
MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for high-impact indications,...
Investors talking about IXHL also mention